Jack Crawford, M.S.
Jack Crawford, M.S.CEO
Mr. Crawford formerly directed the Sales, Marketing, and Business Development Divisions at Transposagen Biopharmaceuticals, Inc. He has experience private equity financing, product development, licensing, technology and patent evaluation. He contributed to nearly all aspects of Transposagen’s rise from pre-revenue start-up to $100M+ valuation (including spin-outs). At Hera, Mr. Crawford is responsible for fundraising, revenue generation, intellectual property development, licensing and corporate governance. Mr. Crawford holds a BS in Biochemistry from Virginia Tech and a Masters in Biotechnology from University of Pennsylvania.
Tseten Yeshi, Ph.D.
Tseten Yeshi, Ph.D.VP, Research & Development
Former Director of R&D at Transposagen. Dr. Yeshi is a molecular biologist and expert in genome editing and with full range experience in performing complex gene editing in a broad array of cell types including rodent embryonic stem cells and spermatogonial stem cells. He has hands on start to finish experience in targeted nuclease design, their on-target and off-target cutting analysis, creation of custom cell lines and rodent models, performing wide-range of molecular and cellular assays for their characterization. Dr. Yeshi has worked extensively with CRISPR/Cas9, TALEN and piggyBac technologies. Particularly combining these technologies for efficient Footprint Free Gene editing: making precise mutations without leaving any undesired changes or “footprint” behind in the genome. Dr. Yeshi has well-developed scientific program management skills and experience, has been a Principle Investigator on multiple NIH SBIR grants and a co-inventor of several patents.
Chris Chengelis, Ph.D.
Chris Chengelis, Ph.D.Senior Scientific Adviser
Former CSO at WIL Research. 35 years+ experience in the preclinical toxicology industry, facility design, study design and execution. Dr. Chengelis has considerable hands on experience, with publications in toxicology and ADME/PK.
Goutham Narla, M.D., Ph.D.
Goutham Narla, M.D., Ph.D.SAB Member & Consultant
The Pardee Gerstacker Professor of Cancer Research and a Medical geneticist at Case Western Reserve University. Dr. Narla is the CSO and Scientific Founder of Dual Therapeutics, Inc. He has expertise in cancer genetics and xenograft and transgenic models of cancer with over 58 publications in the field.
Wei Zhang, Ph.D.
Wei Zhang, Ph.D.Senior Scientist
Dr. Zhang has a background in toxicology and cell biology with multiple publications in the field. She has experience in genetically engineered cell line (knock-in, knockout and reporter cell lines) development, mammalian cell culture and manipulation, bioactivity screening and in vitro toxicity testing. Dr. Zhang has worked extensively with cell based assays measuring cell viability, cell apoptosis, cellular stress, drug metabolism enzymes activity, transporter activity, and gene expression.
Fallon Noto, Ph.D.
Fallon Noto, Ph.D. Senior Scientist
Dr. Noto has 10+ years working with mice and rats, expertise in rodent humanization, cell and tissue transplantation, microsurgery, and ethical animal care with 10+ publications in the field. She is proficient in cell culture techniques of mammalian cells, primary cells, and pluripotent stem cells, including differentiation assays and viral transduction. Dr. Noto is skilled in molecular techniques, including tissue histology, PCR, and protein expression analysis.
Chris Brenzel
Chris BrenzelBusiness Development Manager
Mr. Brenzel is the main point of contact for product and service or partnering inquiries. Contact Chris at cbrenzel @ herabiolabs.com or 859-414-0648. Mr. Brenzel was formerly a Gene Editing Sales Specialist at Transposagen. He has experience in sales, marketing and business development in the fields of contract research services and custom gene editing.
Kamesh Ravi, Ph.D.
Kamesh Ravi, Ph.D. Senior Scientist
Dr. Ravi has 10+ years of experience and 20+ peer-reviewed journal article publications in preclinical oncology, cancer xenograft models, tumor efficacy studies and onco-nephrology. He has a vast experience in designing and executing small and large pre-clinical trials using small molecule inhibitors in various cancer xenograft models. Dr. Ravi is skilled in molecular and cellular assays, tissue histology, gene and protein expression analysis.